Sanofi Stock Discussion

$NLS Pharmaceutics(NLSP.US)$ NASDAQ: VIGL) announced that Sanofi (NASDAQ:SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of its Series A non-voting preferred shares.

$Novavax(NVAX.US)$ sank more than 10% Monday as the vaccine-maker fell for a third straight session following a month-long run-up that boosted the stock more than 400%.
NVAX closed Monday at $16, down 11.9% for the day and 32.9% from the $23.86 19-month intraday high that it hit last Thursday.
Prior to the recent sell-off, Novavax had gained 438.6% between its $4.43 intraday low on May 9 and its $23.86 intraday peak on...

$Sanofi(SNY.US)$
Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.
But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, t...

Meme stock volatility hit the market Monday, sending indexes higher, but shortly before noon EST, the market boomeranged back down. Just after the closing bell, the $S&P 500 Index(.SPX.US)$ had fallen flatly 0.02%, the $Dow Jones Industrial Average(.DJI.US)$ also declined 0.17%, and the $Nasdaq Composite Index(.IXIC.US)$ climbed 0.28%.
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...

$Novavax(NVAX.US)$
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...

Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37% 
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!

📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US)$ & $Regeneron Pharmaceuticals(REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...

$Sanofi(SNY.US)$ out of all the TO targets you choose this one? I would have held out a little longer this isn't the lung one you want. when the dust settles you'll see. I still would have tendered 8-9 B for the other one and see if they bite before. if not it's going for dbl digits. ok m shocked you were my favorite even less then 50%. stupid dark horse is in play.

$Sanofi(SNY.US)$  what a dumb move.